S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Autolus Therapeutics Stock Forecast, Price & News

-0.18 (-4.35%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
458,597 shs
Average Volume
448,671 shs
Market Capitalization
$288.76 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AUTL News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Autolus Therapeutics logo

About Autolus Therapeutics

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.


Why Autolus Therapeutics Stock Jumped 25% Today
November 9, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.72 million
Book Value
$4.01 per share


Net Income
$-142.09 million
Net Margins
Pretax Margin




Free Float
Market Cap
$288.76 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.13 out of 5 stars

Medical Sector

493rd out of 1,418 stocks

Biological Products, Except Diagnostic Industry

75th out of 206 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions

Is Autolus Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Autolus Therapeutics stock.
View analyst ratings for Autolus Therapeutics
or view top-rated stocks.

How has Autolus Therapeutics' stock been impacted by COVID-19?

Autolus Therapeutics' stock was trading at $6.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AUTL shares have decreased by 41.5% and is now trading at $3.96.
View which stocks have been most impacted by COVID-19

Are investors shorting Autolus Therapeutics?

Autolus Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 2,740,000 shares, an increase of 18.1% from the December 15th total of 2,320,000 shares. Based on an average daily trading volume, of 1,180,000 shares, the days-to-cover ratio is currently 2.3 days.
View Autolus Therapeutics' Short Interest

When is Autolus Therapeutics' next earnings date?

Autolus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Autolus Therapeutics

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) released its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.04. The business earned $0.24 million during the quarter, compared to the consensus estimate of $0.25 million. Autolus Therapeutics had a negative net margin of 5,610.45% and a negative trailing twelve-month return on equity of 55.22%. During the same period last year, the company earned ($0.72) earnings per share.
View Autolus Therapeutics' earnings history

What price target have analysts set for AUTL?

6 brokers have issued twelve-month price objectives for Autolus Therapeutics' shares. Their forecasts range from $9.00 to $21.00. On average, they expect Autolus Therapeutics' stock price to reach $14.20 in the next twelve months. This suggests a possible upside of 258.6% from the stock's current price.
View analysts' price targets for Autolus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Autolus Therapeutics' key executives?

Autolus Therapeutics' management team includes the following people:
  • Christian Martin Itin, Chief Executive Officer & Director
  • Christopher Vann, Chief Operating Officer & Senior Vice President
  • Andrew J. Oakley, Chief Financial Officer & Senior Vice President
  • Martin Pulé, Chief Scientific Officer & Senior Vice President
  • David Brochu, Chief Technical Officer & Senior Vice President

What other stocks do shareholders of Autolus Therapeutics own?

When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

What is Autolus Therapeutics' stock symbol?

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Pendal Group Ltd (1.98%).

Which institutional investors are buying Autolus Therapeutics stock?

AUTL stock was bought by a variety of institutional investors in the last quarter, including Pendal Group Ltd.

How do I buy shares of Autolus Therapeutics?

Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Autolus Therapeutics' stock price today?

One share of AUTL stock can currently be purchased for approximately $3.96.

How much money does Autolus Therapeutics make?

Autolus Therapeutics has a market capitalization of $288.76 million and generates $1.72 million in revenue each year. The company earns $-142.09 million in net income (profit) each year or ($2.29) on an earnings per share basis.

How many employees does Autolus Therapeutics have?

Autolus Therapeutics employs 2,020 workers across the globe.

What is Autolus Therapeutics' official website?

The official website for Autolus Therapeutics is www.autolus.com.

Where are Autolus Therapeutics' headquarters?

Autolus Therapeutics is headquartered at FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ.

How can I contact Autolus Therapeutics?

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 442038296230 or via email at [email protected].

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.